SCYX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 20:59):

Stats
Dagens volum	148 825
Gjennomsnittsvolum	204 491
Markedsverdi	67.58M
EPS	$-0.390 ( 2024-03-29 )
Neste inntjeningsdato	( $-0.180 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	1.290
ATR14	$0.00900 (0.50%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-16	Sukenick Scott	Sell	15 179	Common Stock
2024-01-26	Angulo Gonzalez David	Buy	290 590	Common Stock
2024-01-26	Angulo Gonzalez David	Buy	431 030	Employee Stock Option (Right to Buy)
2024-01-26	Macleod Ivor	Buy	215 515	Employee Stock Option (Right to Buy)
2024-01-26	Macleod Ivor	Buy	143 675	Common Stock

INSIDER POWER
98.25
Last 93 transactions
Buy: 4 299 100 \| Sell: 614 179

Volum Korrelasjon

Lang: 0.02 (neutral)

Kort: -0.49 (neutral)

Signal:(52.385) Neutral

SCYNEXIS Inc Korrelasjon

10 Mest positive korrelasjoner
WSBF	0.889
XELA	0.888
ZSAN	0.887
QLGN	0.874
SWVL	0.874
CIVB	0.873
CBAN	0.87
KTTA	0.866
CLBK	0.861
CHMG	0.86

10 Mest negative korrelasjoner
CROX	-0.88
AVAC	-0.874
FNVT	-0.872
GDNR	-0.871
BTWN	-0.87
XENT	-0.869
MLVF	-0.866
ADAL	-0.864
CNGL	-0.863
HWCC	-0.862

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

SCYNEXIS Inc Korrelasjon - Valuta/Råvare

0.42
( neutral )

0.38
( neutral )

0.00
( neutral )

0.27
( neutral )

0.00
( neutral )

-0.44
( neutral )

SCYNEXIS Inc Økonomi

Annual	2023
Omsetning:	$140.14M
Bruttogevinst:	$123.71M (88.27 %)
EPS:	$1.400

FY	2023
Omsetning:	$140.14M
Bruttogevinst:	$123.71M (88.27 %)
EPS:	$1.400

FY	2022
Omsetning:	$5.09M
Bruttogevinst:	$4.46M (87.66 %)
EPS:	$-1.470

FY	2021
Omsetning:	$13.16M
Bruttogevinst:	$12.85M (97.63 %)
EPS:	$-1.250

Financial Reports:

No articles found.

SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.